Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Prospective Observational Study.
chronic kidney disease
complications
diabetes mellitus
glucose
glycated hemoglobin A
hypoglycemia
hypoglycemic agents
prospective studies
risk factors
type 2
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
24 Sep 2020
24 Sep 2020
Historique:
received:
12
03
2020
accepted:
02
07
2020
entrez:
4
4
2022
pubmed:
9
7
2020
medline:
8
4
2022
Statut:
epublish
Résumé
Glycemic management in patients with type 2 diabetes mellitus (T2DM) and CKD can become complicated. One factor that may affect treatment is hypoglycemia. Hypoglycemia risk may be increased by several biologic processes in CKD. The objective of this study was to determine the frequency, severity, and risk factors for hypoglycemia in patients with T2DM and CKD. The design was a prospective observational study. A continuous glucose monitor (CGM) was worn by 80 patients for up to 14 days; glucose was measured every 15 minutes. Patients with T2DM and eGFR <45 ml/min were enrolled. Patients on dialysis were excluded. The primary outcome was to assess the frequency of hypoglycemic episodes during the study period. Hypoglycemic episodes were defined as a reduced glucose concentration (<70 mg/dl) lasting ≥15 minutes. Secondary outcomes included assessment of severity of hypoglycemia and risk factors for its development. A total of 80 patients wore the CGM for a mean of 12.7±2.9 days. Hypoglycemic events occurred in 61 of 80 patients (76%) with glucose <70 mg/dl, and 49 of 80 (61%) with glucose <60 mg/dl. Prolonged hypoglycemic events (CGM glucose <54 mg/dl for ≥120 consecutive minutes) occurred in 31 patients (39%) with 118 total events. Most hypoglycemic episodes occurred overnight, from 1:00 am to 9:00 am. By multivariate analysis, lower hemoglobin A1c and treatment with insulin were two modifiable risk factors for hypoglycemic events. Patients with T2DM and CKD have frequent periods of hypoglycemia that can be severe and prolonged. Hemoglobin A1c does not portray the full scope of hypoglycemia risk. This study illustrates the need for careful monitoring of glucose levels in patients with T2DM and CKD.
Sections du résumé
Background
UNASSIGNED
Glycemic management in patients with type 2 diabetes mellitus (T2DM) and CKD can become complicated. One factor that may affect treatment is hypoglycemia. Hypoglycemia risk may be increased by several biologic processes in CKD. The objective of this study was to determine the frequency, severity, and risk factors for hypoglycemia in patients with T2DM and CKD.
Methods
UNASSIGNED
The design was a prospective observational study. A continuous glucose monitor (CGM) was worn by 80 patients for up to 14 days; glucose was measured every 15 minutes. Patients with T2DM and eGFR <45 ml/min were enrolled. Patients on dialysis were excluded. The primary outcome was to assess the frequency of hypoglycemic episodes during the study period. Hypoglycemic episodes were defined as a reduced glucose concentration (<70 mg/dl) lasting ≥15 minutes. Secondary outcomes included assessment of severity of hypoglycemia and risk factors for its development.
Results
UNASSIGNED
A total of 80 patients wore the CGM for a mean of 12.7±2.9 days. Hypoglycemic events occurred in 61 of 80 patients (76%) with glucose <70 mg/dl, and 49 of 80 (61%) with glucose <60 mg/dl. Prolonged hypoglycemic events (CGM glucose <54 mg/dl for ≥120 consecutive minutes) occurred in 31 patients (39%) with 118 total events. Most hypoglycemic episodes occurred overnight, from 1:00 am to 9:00 am. By multivariate analysis, lower hemoglobin A1c and treatment with insulin were two modifiable risk factors for hypoglycemic events.
Conclusions
UNASSIGNED
Patients with T2DM and CKD have frequent periods of hypoglycemia that can be severe and prolonged. Hemoglobin A1c does not portray the full scope of hypoglycemia risk. This study illustrates the need for careful monitoring of glucose levels in patients with T2DM and CKD.
Identifiants
pubmed: 35369557
doi: 10.34067/KID.0001272020
pii: K3602020000127
pmc: PMC8815604
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
897-903Informations de copyright
Copyright © 2020 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
All authors have nothing to disclose.
Références
Diabetol Metab Syndr. 2016 Jul 28;8:50
pubmed: 27471550
BMJ Open Diabetes Res Care. 2017 Feb 17;5(1):e000320
pubmed: 28243449
Diabetes Care. 2003 May;26(5):1485-9
pubmed: 12716809
BMJ. 2010 Jan 08;340:b5444
pubmed: 20061360
J Diabetes Complications. 2017 Feb;31(2):419-426
pubmed: 27884661
Diabetes. 2008 Dec;57(12):3169-76
pubmed: 19033403
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):844-853
pubmed: 30996047
Curr Med Res Opin. 2016 May;32(5):939-47
pubmed: 26857244
Kidney Med. 2019 Sep 10;1(5):281-287
pubmed: 32734208
Diabetes Care. 2012 Sep;35(9):1897-901
pubmed: 22699297
Curr Diab Rep. 2002 Jun;2(3):237-41
pubmed: 12643179
BMJ. 2010 Jan 08;340:b4909
pubmed: 20061358
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373